Advertisement

Search Results

Advertisement



Your search for Jean-Yves Douillard, MD, PhD matches 7 pages

Showing 1 - 7


ESMO Names George Pentheroudakis, MD, PhD, New Chief Medical Officer

The European Society for Medical Oncology (ESMO) has announced the appointment of George Pentheroudakis, MD, PhD, as its new Chief Medical Officer. Dr. Pentheroudakis is Head of the Department of Medical Oncology at the Ioannina University Hospital in Greece and serves as Professor of Oncology at...

lung cancer

Jean-Yves Douillard, MD, PhD, on New Perspectives in Small Cell Lung Cancer

Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.

colorectal cancer

Overall Survival Improved by Adding Panitumumab to FOLFOX4 but Only in Metastatic Colorectal Cancer Without RAS Mutation

Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 and patients with  other activating RAS mutations do not benefit from anti–epidermal growth factor receptor (EGFR) therapy and may in fact be harmed by it. In an analysis reported in The New England Journal of Medicine ...

Expert Point of View: Jean-Yves Douillard, MD, PhD

Commenting on the RECOURSE data,1 ESMO spokesperson Jean-Yves Douillard, MD, PhD, Professor of Medical Oncology, Institut de Cancérologie de l’Ouest (ICO) René Gauducheau, Saint-Herblain, France, said, “The phase III trial of TAS-102 is a global study and confirms the results of the phase II study...

lung cancer
issues in oncology

High Concordance Between EGFR Mutations From Circulating-Free Tumor DNA and Tumor Tissue in NSCLC

Epidermal growth factor receptor (EGFR) mutations found in the circulating-free tumor DNA from the plasma of advanced non–small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched tumor tissue DNA, according to new data reported by Douillard et...

colorectal cancer

Phase III Trial Shows Improved Survival With TAS-102 in Metastatic Colorectal Cancer Refractory to Standard Therapies

The new combination agent TAS-102 can improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract O-0022). “Around 50%...

colorectal cancer

Presence of RAS Mutations in Metastatic Colorectal Cancer Predictive of Negative Response to Panitumumab/FOLFOX4 Treatment

Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-EGFR therapy. However, other activating RAS mutations may predict poorer outcome with anti-EGFR therapy. In an analysis reported in The New England Journal of Medicine by Jean-Yves Douillard,...

Advertisement

Advertisement



Advertisement